Jeevan Scienti. (538837)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter turned profitable with sales of ₹19 Cr and net profit of ₹2 Cr.
• Sales growth of 52.44% shows strong recent top-line momentum.
• Piotroski F-Score of 7/9 suggests improving operational and financial health.
• Book value per share is positive at ₹24.98, providing some asset backing.
• Small market cap of ₹81 Cr leaves room for meaningful growth if execution improves.

Concerns

• P/E is 0.00 and trailing earnings are effectively absent, making conventional valuation impossible.
• ROE is negative at -2.52% and ROCE is only 2.80%, so current returns on capital are weak for a P/B of 2.04.
• Zero dividend yield means investors get no income while waiting for a recovery.
• Promoter holding and debt/equity are not disclosed, leaving ownership alignment and leverage risk unclear.

AI Analysis

Let me look at Jeevan Scienti through a Graham-Buffett lens. A market cap of ₹81 Cr and price ₹50.96 sounds small, not necessarily cheap. The book value is ₹24.98, so I am being asked to pay 2.04 times book. For that premium, I need evidence that the business earns a strong return on that book. Instead, ROE is negative at -2.52% and ROCE is only 2.80%. That fails any return-on-capital test. The P/E shows 0.00, meaning trailing earnings are not there to support a conventional valuation. Yes, the latest quarter shows sales of ₹19 Cr and net profit of ₹2 Cr, and reported sales growth of 52.44% with profit growth of 1000% looks exciting. But in small companies, percentage growth from a beaten-down base can flatter. One profitable quarter does not establish a durable earning machine. The Piotroski F-Score of 7/9 is the most encouraging thing here; it hints at improving financial health. Still, with zero dividend yield and promoter holding not disclosed, I cannot judge insider alignment. Debt/equity is absent, so I cannot fully assess balance-sheet risk. The 52-week range of ₹32.85 to ₹93.90 shows a stock that has been speculative. This looks like a potential turnaround: a small healthcare research/analytics company showing initial signs of life, but not yet a proven compounder. I need years of consistent profits, higher ROE, and honest disclosures before paying 2x book. I would wait for a margin of safety.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer